OS-SiA is the industry’s first AI-enabled digital scanner that will provide real-time predictive analysis and actionable insights
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
Already an existing partner and supplier of ingredients to Medisca, striking this agreement with SUANFARMA involved reinforcing a well-established symbiotic relationship between two companies committed to world-class quality, service, and price
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
Lung cancer is the leading cause of cancer death in the USA, making up almost 25% of all cancer deaths
Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
The aim is to provide further insights into patients' lives in the effort to deliver better outcomes for people with psoriatic arthritis (PsA)
Subscribe To Our Newsletter & Stay Updated
